SLC10A1 and liver cancer: An efficient prophylactic approach using combination of drugs which inhibits HBV cell entry (NTCP surface expression inhibitors, and NTCP-preS1 interaction direct blockers) might be beneficial as an alternative to HBIG to efficiently suppress NTCP-mediated HBV infection and prevent HBV-related complications like HBV DNA integration and HBV-induced liver cancer.